AGT and Hyperkalemia: Moreover, a phase 1 study (URL: https://www.clinicaltrials.gov; Unique identifier: NCT03934307) in patients with hypertension revealed that zilebesiran, an investigational subcutaneously administered GalNAc-siRNA therapeutic targeting hepatic AGT, not only lowered serum AGT in a dose-dependent manner (>90% at a dose of 800 mg) but also reduced blood pressure at single doses of ≥200 mg for up to 24 weeks.3 Single doses of zilebesiran were well tolerated, with no observed hypotension, hyperkalemia, or worsening renal function.